| 07/22/07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/22/06 | Notification about results of final buy-back of shares | AQ |
| 30/21/30 | Notification about final share buy-back | AQ |
| 28/21/28 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/21/28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04/08/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 15Cr | |
| +0.83% | -2.24% | +22.63% | +68.52% | 4.9TCr | |
| +3.09% | +7.65% | +60.81% | +132.38% | 3.94TCr | |
| +1.28% | +0.79% | -0.59% | +20.79% | 1.24TCr | |
| -0.92% | -0.36% | +19.13% | +69.58% | 1.18TCr | |
| 0.00% | -0.38% | +30.75% | +134.53% | 914.14Cr | |
| +1.34% | +3.50% | +15.77% | +35.84% | 704.69Cr | |
| +1.61% | -4.86% | +36.73% | -14.17% | 686.21Cr | |
| +0.71% | +3.85% | +12.29% | +178.75% | 670.43Cr | |
| +0.79% | +3.84% | -29.57% | +15.81% | 567.22Cr | |
| Average | +1.60% | -0.26% | +18.66% | +71.34% | 1.64TCr | |
| Weighted average by Cap. | +1.35% | -0.33% | +28.93% | +83.26% |
Employees
2,191
Sector
Pharmaceuticals
